NEW YORK (Reuters Health) – There’s no evidence that starting treatment with the anti-obesity drug orlistat raises the likelihood of developing colorectal cancer, at least in the short…
NEW YORK (Reuters Health) – The psychostimulant modafinil is no better than a placebo in improving fatigue, depression and cognitive function in patients with primary brain tumors (PBT),…
NEW YORK (Reuters Health) – The addition of bevacizumab to adjuvant chemotherapy does not improve invasive disease-free rates in women after resection of breast cancer that’s negative for…
By Will Boggs, MD NEW YORK (Reuters Health) – Patients with unresectable primary spinal sarcoma may benefit from carbon ion radiotherapy (CIRT), Japanese researchers say. Compared with proton…
NEW YORK (Reuters Health) – Recurrence after limited lung resection for small early-stage adenocarcinoma is three times more likely when the micropapillary component of the tumor is 5%…
NEW YORK (Reuters Health) – In a phase III, multinational study of patients with heavily pretreated metastatic breast cancer, adding sunitinib to capecitabine provided no benefit, and in…
NEW YORK (Reuters Health) – The results of a phase III Italian study indicate that the risk of breast cancer in postmenopausal women who use hormone replacement therapy…
NEW YORK (Reuters Health) – Chemotherapy given in conjunction with regional hyperthermia produces good response rates in children and adolescents with refractory or recurrent germ-cell tumors, German researchers…
NEW YORK (Reuters Health) – When the cell adhesion molecule L1CAM is expressed in early-stage endometrial tumors, there is a 50% chance of recurrence, a multicenter study has…
By Andrew M. Seaman NEW YORK (Reuters Health) – Low-dose aspirin, even if not taken daily, may reduce a woman’s risk of colon cancer over the long term,…
